Virongy Biosciences
Accelerate Discovery

CAPABILITY STATEMENT

SNAPSHOT

POINT OF CONTACT:
Brian Hetrick, CEO
Brian.Hetrick@virongy.com
703-257-5500

HEADQUARTERS: **Virginia**
UNIQUE ENTITY ID:
XGY3Q7EZ9JA7
CAGE CODE: **99T06**
NAICS: **541715, 541714, 325413, 325414**
COMPLIANCES:
ISO 90001:2015
ISO/IEC 17025:2017
ANSI/AAMI/ISO 10993-5:2009

CORE COMPETENCIES

SERVICES

- Neutralization Assay Services
- Antiviral and Antibody Discovery
- Development of Viral Assays
- Pseudovirus Production
- BSL2 level virus production
- Manufacturing of Custom Viral Vectors
- Manufacturing of Viral Standards
- Manufacturing Virus-Like-Particles (VLPs)
- Viral Outgrowth and Recovery
- Reporter Virus Design and Manufacturing
- Hybridoma and Cell Line Generation
- CRSPR-Cas9 gene knockout
- ShRNA/SiRNA gene knockdown
- Expression Vector Design and Synthesis
- Peptide Synthesis
- Infectious Disease Detection and Quantification Assays
- Experimental Design
- Report Writing

PROJECT TYPES

- Antibody and Antiviral Screening
- Custom Reporter Virus Generation
- Viral Vector Development
- Virus Recovery and Isolation
- Virus Propagation
- Viral Assay Development
- Custom Cell Line Engineering

CORPORATE OVERVIEW

Virongy Biosciences Inc. is a biotechnology company dedicated to advancing viral vector technologies, diagnostic tools, and the discovery of antivirals and antibodies for viral pathogens critical to public health and biodefense. Our patented platforms, including Alpha-pseudoviruses, advanced AAV encapsulation, and Infectin™ technologies, enable rapid quantification of antivirals and neutralizing antibodies, as well as enhanced gene therapy delivery. Committed to continuous innovation and backed by decades of virology expertise, we empower clients to accelerate discoveries and address emerging viral threats.

DIFFERENTIATORS

PATENTED PSEUDOVIRUS AND VIRAL VECTOR PLATFORMS
PATENTED INFECTIN™ TECHNOLOGY ENHANCED SERVICES
RAPID ADAPTATION FOR EMERGING PATHOGENS
EXPERT SUPPORT FROM AWARD WINNING VIROLOGISTS

PAST PERFORMACE

CDC

Assessed emerging SARS-CoV-2 variants to evaluate infectivity, immune escape and their potential viral threat to public health using the Alpha-pseudovirus technology. Over 50 viral variants were screened to identify those with the highest infectivity, and neutralization assays were conducted to determine their sensitivity to antibodies from vaccines and prior infections.

ATCC

BEI RESOURCES
SUPPORTING INFECTIOUS DISEASE RESEARCH

Completed multiple viral outgrowth projects for ATCC under the BEI Resources contract. Utilizing Infectin™, HIV isolates where grown to high titer, including samples over 30 years old that were no longer viable through standard outgrowth techniques.

THE UNIVERSITY of NORTH CAROLINA at CHAPEL HILL

Provided the University of North Carolina Chapel Hill's Vaccine Research Center with neutralization assays utilizing the Alpha-pseudovirus technology. Enabling accurate SARS-CoV-2 vaccine efficacy testing during an early-phase clinical trial

NIH National Institute of Allergy and Infectious Diseases

Completed multiple projects for NIH's NIAID and NCI, including providing neutralization assays for various high-risk pathogens such as avian influenza, MERS-CoV and SARS-CoV-2. Designed and manufactured custom lentiviral vectors and completed multiple custom cell line productions.